Sera Prognostics (SERA) Competitors

Sera Prognostics (NASDAQ:SERA) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Do insiders & institutionals have more ownership in SERA or TOI?

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 13.5% of Sera Prognostics shares are held by insiders. Comparatively, 8.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media favor SERA or TOI?

In the previous week, Sera Prognostics had 1 more articles in the media than Oncology Institute. MarketBeat recorded 3 mentions for Sera Prognostics and 2 mentions for Oncology Institute. Sera Prognostics' average media sentiment score of 1.35 beat Oncology Institute's score of 0.94 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncology Institute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SERA or TOI more profitable?

Oncology Institute has a net margin of -14.26% compared to Sera Prognostics' net margin of -30,306.48%. Sera Prognostics' return on equity of -45.86% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-30,306.48%	-45.86%	-34.31%
Oncology Institute	-14.26%	-1,527.21%	-34.25%

Which has more risk & volatility, SERA or TOI?

Sera Prognostics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500.

Which has better earnings and valuation, SERA or TOI?

Sera Prognostics has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,450.30	-$32.90M	-$0.85	-3.62
Oncology Institute	$393.41M	0.83	-$64.66M	-$0.68	-5.12

Do analysts rate SERA or TOI?

Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 101.15%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts plainly believe Oncology Institute is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oncology Institute	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Summary

Sera Prognostics beats Oncology Institute on 9 of the 17 factors compared between the two stocks.